shionogi

What's New Index

2011

2011/07/19 Shionogi Inc. Signs Agreement to Expand its Portfolio with Acquisition of Nine Marketed Products From Victory Pharma, Inc.
2011/07/12 License Agreement for the Sale of Pirfenidone (PirespaŽ) in South Korea with ILDONG PHARMACEUTICAL
2011/07/11 Shionogi to Determine the Contents of Stock Options as Compensation (Stock Acquisition Rights)
2011/06/24 Shionogi to Issue of Stock Options as Compensation (Stock Acquisition Rights) to Members of Board of Directors
2011/05/16 Audio Webcasting of Conference for the Year ended March 31, 2011
2011/05/09 Shionogi to Introduce Stock Options as Compensation (Stock Acquisition Rights) to Members of Board of Directors
2011/05/09 Financial Statements for the Year ended March 31, 2011
2011/04/25 Notice of Revisions of Earnings Forecasts
2011/04/22 Shionogi Receives Approval of Additional Dosage and Administration of Carbapenem Antibiotic Products: Finibax® 0.25g IV Solution and Finibax® 0.25g IV Solution Kit
2011/04/07 Shionogi Inc. Press Release: Shionogi Announces Commercial Availability of CUVPOSA (glycopyrrolate) Oral Solution for Pediatric Chronic Severe Drooling Associated with Neurologic Conditions
2011/04/04 Shionogi Inc. Press Release: Shionogi Announces New US Leadership
2011/04/04 Impact of the 2011 Great Eastern Japan Earthquake (3rd Report)
2011/04/01 Shionogi Signs Agreement with Denmark on International Industry-Academic Collaboration Initiatives
2011/03/18 Audio Webcasting of the R&D Meeting
2011/03/16 Impact of the 2011 off the Pacific coast of Tohoku Earthquake (2nd Report)
2011/03/15 Impact of the 2011 off the Pacific coast of Tohoku Earthquake
2011/03/10 R&D Meeting
2011/02/21 Shionogi Announces Appointment of Directors, Corporate Officers and Corporate Reorganization
2011/02/04 Audio Webcasting of Conference Call for the Third Quarter of Fiscal Year 2010
2011/02/03 Shionogi-ViiV Healthcare Starts Phase III Trial for "572-Trii" Fixed-Dose Combination HIV Therapy
2011/01/31 Outsourcing Agreement on Distribution Operation
2011/01/31 Dissolution of a Consolidated Subsidiary
2011/01/31 Financial Results for the Third Quarter of Fiscal Year 2010
2011/01/11 Shionogi Inc. Press Release: Shionogi Inc. Announces Commercial Availability of KAPVAY (clonidine hydrochloride) Extended-Release Tablets for the Treatment of ADHD

2010

2010/12/27 Shionogi to enter into licensing agreement on NF-kappaB Decoy Oligodeoxynucleotide for Atopic Dermatitis with AnGes MG, Inc.
2010/12/06 Shionogi has entered into a licensing agreement on peptide vaccines for ophthalmic disease with OncoTherapy Science, Inc.
2010/11/09 Audio Webcasting of Conference Call for the Second Quarter of Fiscal Year 2010
2010/11/01 Financial Results for the Second Quarter of Fiscal Year 2010
2010/11/01 Shionogi to make its subsidiary into a wholly owned subsidiary, and to change the corporate name
2010/10/28 Shionogi and GlaxoSmithKline to collaborate on the research, development and commercialization of novel antibiotics targeting drug-resistant Gram-negative bacteria
2010/10/27 Shionogi Receives an Approval foran Additional Indication for Pediatric Use of RAPIACTA®, a Novel Anti-viral Drug for Influenza
2010/10/22 Notice of Revisions of Earnings Forecasts
2010/10/21 Shionogi-ViiV Healthcare LLC Initiates Phase III Clinical Programme for Investigational Once-Daily HIV Integrase Inhibitor
2010/10/20 Shionogi reached an agreement to settle patent-infringement lawsuit for Flomox® (Oral cephem antibiotic agent)
2010/10/15 Shionogi Signs Agreement with Sweden on International Industry-Academic Collaboration Initiatives
2010/10/05 Shionogi Inc. Press Release: SHIONOGI ANNOUNCES FDA APPROVAL OF KAPVAY - THE FIRST AND ONLY THERAPY APPROVED FOR USE WITH STIMULANT MEDICATION FOR THE TREATMENT OF ADHD
2010/09/28 Establishment of an Organization and Personnel Reassignment
2010/09/07 License agreements with Stallergenes regarding sublingual allergen immunotherapy tablets
2010/09/01 Shionogi Inc. Press Release: Confirmation of SHIONOGI ANNOUNCES POSITIVE OUTCOME TO THE DECENTRALIZED PROCEDURE FOR THE EUROPEAN APPROVAL OF TWINJECT® (EPINEPHRINE AUTO-INJECTOR)
2010/09/01 Dissolution of a Subsidiary
2010/08/06 Audio Webcasting of Conference Call for the First Quarter of Fiscal Year 2010
2010/08/02 First Quarter of Fiscal Year 2010 Conference Call
2010/08/02 Financial Results for the First Quarter of Fiscal Year 2010
2010/07/30 SHIONOGI INC. ANNOUNCES FDA APPROVAL OF CUVPOSA FOR THE TREATMENT OF CHRONIC SEVERE DROOLING IN PEDIATRIC PATIENTS WITH NEUROLOGIC CONDITIONS
2010/07/23 Shionogi-ViiV Healthcare LLC Presents Positive Data on Investigational Once-Daily Integrase Inhibitor at International AIDS Conference
2010/07/21 Shionogi-ViiV Healthcare Announces Commitment to Phase III Development Programme for Investigational Once-Daily HIV Integrase Inhibitor
2010/07/01 Shionogi announces reorganization of US Operations, new leadership.
2010/06/30 CRESTOR® PATENT UPHELD BY US DISTRICT COURT, DISTRICT OF DELAWARE
2010/06/17 Establishment of an Organization
2010/06/01 PIVOTAL DATA FOR THE INVESTIGATIONAL TREATMENT PSD502 FOR PRIMARY PREMATURE EJACULATION IN THE UNITED STATES TO BE PRESENTED AT MAJOR MEDICAL MEETING
2010/06/01 Shionogi Announces the Conducting of Drug Discovery Competition FINDS2010 -Drug seeds fostering type-
2010/05/17 Audio Webcasting of Conference for the Year ended March 31, 2010
2010/05/10 Financial Statements for the Year ended March 31, 2010
2010/05/10 Shionogi Establishes Shionogi Techno Advance Research Co., Ltd.
2010/05/10 New Quinolone Oral Antibiotic Avelox®: Sales Rights Transfer
2010/04/27 Shionogi Appeals Patent Infringement lawsuit for Flomox® (Oral cephem antibiotic agent) to the Intellectual Property High Court
2010/04/16 Launch of an Antidepressant Drug,“Cymbalta® Capsules 20mg and 30mg”
2010/03/25 Audio Webcasting of Conference for SHIONOGI'S THIRD MEDIUM-TERM BUSINESS PLAN
2010/03/16 SHIONOGI'S THIRD MEDIUM-TERM BUSINESS PLAN (presentations)
2010/03/16 SHIONOGI'S THIRD MEDIUM-TERM BUSINESS PLAN
2010/03/11 Shionogi and TAKATA SEIYAKU Announce Agreement on Succession of Marketing and Manufacturing Rights
2010/03/02 SHIONOGI ENTERS INTO EXCLUSIVE LICENSE AGREEMENT WITH QUATRX PHARMACEUTICALS TO MARKET OSPEMIFENE
2010/02/22 NOTIFICATION OF SUBSIDIARY TRANSFER
2010/02/22 Shionogi Announces Appointment of Directors, Corporate Officers and Corporate Reorganization
2010/02/15 Shionogi Files an Additional Application for Pediatric Use of “RAPIACTA®” a Novel Anti-viral Drug for Influenza
2010/02/05 Audio Webcasting of Conference Call for the Third Quarter of Fiscal Year 2009
2010/02/01 Financial Results for the Third Quarter of Fiscal Year 2009
2010/01/26 A Novel Anti-viral Drug for Influenza,“RAPIACTA 300mg Bag for Intravenous Drip Infusion” and “RAPIACTA 150mg Vial for Intravenous Drip Infusion” Launch
2010/01/25 Shionogi Supports Relief Efforts for Haiti Earthquake Victims
2010/01/20 Shionogi Receives Marketing and Manufacturing Approval of an Antidepressant Drug,“Cymbalta ®Capsules 20mg and 30mg”
2010/01/13 Shionogi Receives Marketing and Manufacturing Approval of a Novel Anti-viral Drug for Influenza, “RAPIACTA 300mg Bag for Intravenous Drip Infusion” and “RAPIACTA 150mg Vial for Intravenous Drip Infusion”
2010/01/12 SCIELE PHARMA, INC., A SHIONOGI GROUP COMPANY, ANNOUNCES NAME CHANGE
2010/01/07 Sciele Pharma introduces Adrenaclick auto-injector for the emergency treatment of anaphylaxis

2009

2009/11/19 Sciele Pharma presents PSD502 clinical data for the treatment of premature ejaculation at a medical conference, SMSNA
2009/11/16 SCIELE PHARMA, A SHIONOGI COMPANY, TO ACQUIRE ADDRENEX PHARMACEUTICALS, INC., A U.S. SPECIALTY PHARMACEUTICAL COMPANY
2009/11/10 Audio Webcasting of Conference Call for the Second Quater of Fiscal Year 2009
2009/11/04 Financial Results for the Second Quater of Fiscal Year 2009
2009/11/04 Shionogi Filed a New Drug Application for Peramivir, a Novel Anti-viral Drug for Influenza
2009/10/30 Shionogi Announces the 2009 Results of Drug Discovery Competition
2009/10/09 Shionogi Signs Agreement with United Kingdom on International Industry-Academic Collaboration Initiatives
2009/10/01 Sciele Pharma announces the sNDA submission to the FDA for Clonicel to treat ADHD
2009/09/28 Sciele Pharma announces the NDA submission to the FDA for Glycopyrrolate
2009/09/15 Antiviral Activity of S/GSK1265744, a Once-Daily, Unboosted Integrase Inhibitor in Clinical Development, Evaluated in Phase 1-2a Study in Healthy and HIV-Infected Subjects
2009/09/14 Cancer Pain Analgesic Additional Volume of OxiNorm® Powder 0.5% 2g (10mg/pouch)
2009/09/11 Shionogi Annual Report 2009
2009/08/19 Personnel Reassignments
2009/08/18 Shionogi Files a Patent Infringement Action against a Generic Company for Flomox® (Oral cephem antibiotic agent)
2009/08/13 Shionogi-GSK acknowledges position of European AIDS patient advocacy groups to revise protocol for Phase Ilb study for S/GSK1349572
2009/08/07 Audio Webcasting of Conference Call for the First Quarter of Fiscal Year 2009
2009/08/03 Financial Results for the first Quarter of Fiscal Year 2009
2009/08/03 Shionogi Announces the Reduction of the Minimum Investment Unit and an Amendment to its Articles of Incorporation
2009/07/29 Sciele Pharma announces Positive Results of Final Phase III Pivotal Trial for PSD502 for premature ejaculation
2009/07/29 Personnel Reassignments
2009/07/21 Antiviral activity of S/GSK1349572, the only once-daily, unboosted integrase inhibitor in clinical development, evaluated in phase 2 study
2009/07/17 Shionogi announces positive results from Phase3 studies of peramivir, a novel anti-viral drug for influenza
2009/07/10 SCIELE PHARMA, A SHIONOGI COMPANY, TERMINATES AGREEMENT TO ACQUIRE VICTORY PHARMA, INC.
2009/07/09 Sciele Pharma announces availability of Ulesfia lotion, first prescription non-neurotoxic head lice treatment
2009/06/04 Notification with Respect to Issuance of Unsecured Straight Bonds
2009/06/01 Shionogi Announces the Conducting of Drug Discovery Competition "FINDS" in 2009
2009/05/26 Sciele Pharma acquires global rights for PSD502 from Plethora Solutions
2009/05/18 SCIELE PHARMA, A SHIONOGI COMPANY, TO ACQUIRE VICTORY PHARMA, INC., A U.S. SPECIALTY PHARMACEUTICAL COMPANY
2009/05/15 Fluitran® 1mg Tablets Launches
2009/05/11 Shionogi Announces an Amendment to its Articles of Incorporation
2009/05/11 Position and Policies Concerning the Reduction of the Minimum Investment Unit
2009/05/11 Financial Statements for the Year ended March 31, 2009
2009/04/28 Sciele Pharma announces that PSD502 demonstrates substantial benefit in the treatment of premature ejaculation
2009/04/23 Sciele Pharma, Inc. announces positive phase III clinical results of Clonicel used in combination with stimulants to treat ADHD
2009/04/13 Sciele Pharma, Inc. announces FDA approval of first prescription non-neurotoxic head lice treatment.
2009/03/30 Establishment of an Organization and Personnel Reassignments
2009/03/27 R&D Meeting
2009/03/16 Shionogi establishes "Medicinal Molecular Imaging Center (Tentative)" in order to promote joint research with Osaka University Graduate School of Medicine and Faculty of Medicine
2009/03/16 Shionogi Announces Introduction of External Board Members Appointment of Directors and Corporate Officers
2009/02/23 Shionogi establishes Ezose Sciences, a jointly-owned US venture company providing serum glycan analysis services
2009/02/19 Shionogi Files Patent Infringement Actions against a Bulk Powder Import Company and Files Suspension of Import with Customs for Flomox ® (Oral cephem antibiotic agent)
2009/02/18 Sciele Pharma, Inc. announces the completion of patient recruitment for global phase III trial of PSD502 for Premature Ejaculation.
2009/02/17 Shionogi announces positive top-line efficacy results from year-long studies of velneperit, a novel NPY Y5 receptor antagonist being investigated for the treatment of obesity
2009/02/04 Sciele Pharma, Inc. announces the launch of PrandiMet ® for the treatment of Type 2 Diabetes.
2009/02/02 Shionogi announces it has entered into a licensing agreement on Peptide vaccines for cancer treatment with OncoTherapy Science, Inc.
2009/02/02 Corporate Reorganization and Personnel Reassignments
2009/02/02 Notice of Revision of Earnings Forecast for the Year Ending March 31, 2009
2009/02/02 Financial Results for the Third Quater of Fiscal Year 2008

2008

2008/12/12 Pirespa® 200mg Tablet Launched Idiopathic Pulmonary Fibrosis Treatment
2008/11/26 Additional Adult Indication Approved for Flomox ® Fine Granules 100mg for children Oral cephem antibiotic agent
2008/11/11 Shionogi Announces Completion of Construction of a New Facility for Formulation and Packaging of Solid Dosage Forms at the Settsu Plant
2008/11/04 Financial Results for the Second Quater of Fiscal Year 2008
2008/10/31 Shionogi Announces the 2008 Results of Drug Discovery Competition
2008/10/16 Shionogi Receives Marketing and Manufacturing Approval for Pirespa® 200mg Tablets Idiopathic Pulmonary Fibrosis Treatment
2008/10/14 A novel topical treatment for acne vulgaris Differin® Gel 0.1% Launches
2008/10/10 Shionogi and Siele Announce Completion of Subsequent Offering Period
2008/10/10 Shionogi Completes Acquisition of Sciele
2008/10/06 Shionogi and Sciele Announce successful tender offer and commencement of subsequent offering
2008/09/19 Shionogi and Sciele Announce Receipt of United States Antitrust Clearance
2008/09/16 Shionogi Annual Report 2008
2008/09/01 Acquisition of Sciele Pharma, Inc.
2008/09/01 Shionogi & Co., Ltd. Acquires US-based Sciele Pharma, Inc.
2008/07/28 Financial Results for the first Quarter of Fiscal Year 2008
2008/07/16 Marketing and Manufacturing Approval for Differin® Gel 0.1%
2008/06/23 Angiotensin II Receptor Blockers (ARBs) for treatment of Hypertension Irbetan® 50mg and 100mg Tablets Launches
2008/05/30 Shionogi Establishes Joint Research Facility, “Shionogi Innovation Center for Drug Discovery”with Hokkaido University
2008/05/12 Financial Statements for the Year ended March 31, 2008
2008/05/12 Position and Policies Concerning the Reduction of the Minimum Investment Unit
2008/04/23 Shionogi Announces the Conducting of Drug Discovery Competition “FINDS” in 2008
2008/04/21 Notice of Revision of Dividend Forecast for Year Ended March 31, 2008
2008/04/17 Shionogi Receives Marketing and Manufacturing Approval for Irbetan® 50mg and 100mg Tablets
2008/03/18 R&D Meeting
2008/03/17 Changes of Representative Directors and Corporate Officers
2008/02/27 Corporate Reorganization and Personnel Reassignments
2008/01/28 Construction of New Research Facility
2008/01/28 Third Quarter Financial Results (Consolidated) for the Year ending March 31, 2008
2008/01/21 Claritin® Dry Syrup 1% Launched

2007

2007/12/12 Shionogi Files Patent Infringement Actions in Response to Crestor® ANDAs in the USA
2007/11/08 Notice of Execution and Completion of Acquisition of the Company's Own Shares
2007/11/05 Interim Financial Statements for the six months ended September 30, 2007
2007/10/31 Shionogi Announces the 2007 Results of Drug Discovery Competition FINDS
2007/10/19 Additional Pediatric Indication Approved for Claritin®
2007/10/19 Approval received for Claritin® Dry Syrup 1%
2007/10/16 Notice of Execution of Acquisition of the Company's Own Shares
2007/10/02 Establishment of Shionogi Analysis Center Co., Ltd.
2007/09/27 Annual Report 2007
2007/09/18 Notice of Acquisition of the Company's own shares
2007/07/30 First Quarter Financial Results (Consolidated) for the Year ending March 31, 2008
2007/05/14 Financial Statements for the Year ended March 31, 2007
2007/05/14 Shionogi Announces an Amendment to Its Articles of Incorporatiojn
2007/05/14 Position and Policies Concerning the Reduction of the Minimum Investment Unit
2007/04/20 PRIME Program “Report of Results of CRESTOR® Usage Outcome Survey of Approximately 10,000 Japanese Subjects”
2007/04/16 Shionogi Announces the Opening of Drug Discovery Competition FINDS
2007/04/05 Shionogi Announces Revisions to the Second Medium-Term Business Plan(Presentation)
2007/04/04 Shionogi Announces Revisions to the Second Medium-Term Business Plan
2007/04/04 Notice of Revision of Results Forecast for the Year Ended March 31, 2007
2007/03/26 Shionogi Announces Organizational and Personnel Changes
2007/03/22 R&D Meeting
2007/02/26 Environmental Report 2006
2007/02/05 Shionogi Launches Cancer Pain Analgesic OxiNorm Powder 0.5%
2007/02/02 Eli Lilly Japan and Shionogi to Co-Develop and Co-Market Duloxetine in Japan
2007/02/02 Environmental Report 2006
2007/01/29 Third Quarter Financial Results(Consolidated) for the Year ending March 31,2007

2006

2006/12/22 Results of Phase III Clinical Trials of the Idiopathic Pulmonary Fibrosis Treatment S-7701
2006/10/27 Shionogi Discontinues Development of S-5751, a Prostaglandin D2 Receptor Antagonist
2006/10/20 Shionogi Obtained Manufacturing and Marketing Approval for Cancer Pain Analgesic OXINORM powder 0.5%
2006/10/19 Announcement of Final Results of JATOS, Japan's First Large-Scale Clinical Trial for Treatment of Hypertension in Elderly Patients
2006/10/05 Basic Agreement Reached on Construction of Joint Research Facility
2006/09/21 Launch of Premature Ovulation Inhibitor Cetrotide®0.25mg and 3mg for Injection (Cetrorelix Acetate)
2006/09/21 Annual Report 2006
2006/08/15 GLAXOSMITHKLINE AND SHIONOGI COMPLETE INITIAL CLINICAL STUDY FOR HIV INTEGRASE INHIBITOR
2006/08/07 The analysis from the interim report of post-marketing surveillance for Crestor® submitted to the regulatory authority
2006/07/31 First Quarter Financial Results (Consolidated) for the Year ending March 31, 2007
2006/07/10 Shionogi announces positive results from a Phase IIa study of S-2367, a novel neuropeptide Y5 receptor antagonist for the treatment of Obesity
2006/07/07 Shionogi to Launch Non-pyrazolone Antipyretic Analgesic “Sedes®V”
2006/06/09 Shionogi Launches Carbapenem Antibiotic Product “Finibax®0.25g IV Solution Kit”
2006/05/16 Marketing Agreement for Rapid BNP Test “SHIONOSPOT® BNP” and the Associated Measurement System “SHIONOSPOT® Reader”
2006/04/24 Notice of Revision of Dividend Forecast for Year Ended March 31,2006
2006/04/20 Manufacturing and Marketing Approval for Premature Ovulation Inhibitor Cetrotide®(Cetrorelix Acetate) Obtained
2006/03/07 Shionogi and Galderma Announce Memorandum of Understanding Regarding Adapalene gel 0.1%, a topical treatment of acne vulgaris
2006/01/10 Shionogi and Purdue Pharma L.P. Sign Multi-Year Research and Worldwide Co-Marketing Agreement for Novel Analgesic Drug Compounds

page top